In this issue:
Long-term safety of certolizumab pegol in plaque psoriasis
Tildrakizumab for psoriasis with metabolic syndrome
Network meta-analysis of biologics in psoriasis using absolute PASI
Long-term risankizumab for moderate-to-severe chronic plaque psoriasis
Spesolimab for palmoplantar pustulosis
Long-term patient-reported outcomes with ixekizumab for plaque psoriasis
Drug survival of ixekizumab and TNF, and other IL-17 inhibitors
Secukinumab normalises QoL and disease symptoms
Please login below to download this issue (PDF)